"Carter Worth and the panel argued that biotech is completing a long-term bottoming process and offers relative and absolute upside as M&A accelerates."

"The thesis argued is that Eli Lilly is establishing single-player market dominance in GLP-1 weight loss therapies through superior trial efficacy stories and product execution over Novo Nordisk."